Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 5/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.40 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.34 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.34 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.33 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | STAT6 | P42226 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891669 | 0.80 | KMT2A (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7404499 | 0.77 | EPHX2 (0.37) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL891885 | 0.75 | — | — | |
| SCHEMBL6756192 | 0.75 | FAAH (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL27740241 | 0.74 | NPFFR1 (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL28089950 | 0.74 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL27921465 | 0.72 | GRIN2D (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL140990 | 0.69 | GRIN2D (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL16354052 | 0.69 | — | — | |
| SCHEMBL892469 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530234-B2 | CD73 inhibitors and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-12-20 | — | — | US | claimed |
| CN-115443293-A | Composition for encapsulating organic light emitting element and organic light emitting display device comprising same | 索路思高新材料有限公司 | 2022-12-06 | — | — | CN | claimed |
| EP-3849992-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-07-21 | — | — | EP | claimed |
| US-20210139526-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN (SUZHOU) PHARMA TECH Co.,Ltd. (CN) | 2021-05-13 | — | — | US | claimed |
| CN-112771061-A | CD73 inhibitor and pharmaceutical application thereof | 润佳（苏州）医药科技有限公司 | 2021-05-07 | — | — | CN | claimed |
| US-10881681-B2 | CD73 inhibitors and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-01-05 | — | — | US | claimed |
| WO-2020051686-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN (SUZHOU) PHARMA TECH CO. LTD. (CN) | 2020-03-19 | — | — | WO | claimed |
| CN-110885352-A | CD73 inhibitor and pharmaceutical application thereof | 润佳（苏州）医药科技有限公司 | 2020-03-17 | — | — | CN | claimed |
| US-20200078388-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) | 2020-03-12 | — | — | US | claimed |
| US-8901155-B2 | Method for treating a TRPV1-mediated disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-12-02 | — | — | US | claimed |
| US-20130090359-A1 | METHOD FOR TREATING A TRPV1-MEDIATED DISEASE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-11 | — | — | US | claimed |
| US-20100261911-A1 | THERAPEUTIC AGENT FOR TRPV1-MEDIATED DISEASE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | claimed |
| EP-2210878-A1 | THERAPEUTIC AGENT FOR TRPV1-MEDIATED DISEASE | Santen Pharmaceutical Co., Ltd (JP) | 2010-07-28 | — | — | EP | claimed |
| WO-2008009963-A2 | PYRIMIDINE DERIVATIVES AS MODULATORS OF PARATHYROID HORMONE RECEPTORS | JAMES BLACK FOUNDATION LIMITED (GB) | 2008-01-24 | — | — | WO | claimed |
| EP-0882023-B1 | HISTAMINE H 3 RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2003-06-04 | — | — | EP | claimed |
| US-6080871-A | ANTIHISTAMINES | JAMES BLACK FOUNDATION LIMITED (GB) | 2000-06-27 | — | — | US | claimed |
| EP-0882023-A1 | HISTAMINE H 3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1998-12-09 | — | — | EP | claimed |
| WO-1997029092-A1 | HISTAMINE H3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1997-08-14 | — | — | WO | claimed |
| EP-0531382-A1 | N-SUBSTITUTED-1,2,4-TRIAZOLONE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1993-03-17 | — | — | EP | claimed |
| WO-1991018888-A1 | N-SUBSTITUTED-1,2,4-TRIAZOLONE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-12-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200078388-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | ENTPD5, ENTPD1, NT5E | GRIN2D 4128/4885GRIN3B 2853/4885GRIN1 2629/4885 |
| US-10881681-B2 | CD73 inhibitors and pharmaceutical uses thereof | ENTPD5, ENTPD1, NT5E | GRIN2D 4128/4885GRIN3B 2853/4885GRIN1 2629/4885 |
| US-20100261911-A1 | THERAPEUTIC AGENT FOR TRPV1-MEDIATED DISEASE | TRPV1, TRPA1, TRPV3 | GRIN2D 1943/4885GRIN3B 603/4885GRIN1 378/4885 |
| US-20130090359-A1 | METHOD FOR TREATING A TRPV1-MEDIATED DISEASE | TRPV1, TRPV3, TRPV2 | GRIN2D 752/4885GRIN3B 508/4885GRIN1 294/4885 |
| US-11530234-B2 | CD73 inhibitors and pharmaceutical uses thereof | ENTPD5, ENTPD1, NT5E | GRIN2D 4128/4885GRIN3B 2853/4885GRIN1 2629/4885 |
| US-20210139526-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | ENTPD5, ENTPD1, NT5E | GRIN2D 4128/4885GRIN3B 2853/4885GRIN1 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.